Medpace Holdings Inc vs Omnicom Group Inc. — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Omnicom Group Inc. trades at $85.75 (market cap $23.58B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.72% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | OMC | |
|---|---|---|
Market Cap | $16.90B | $23.58B |
Sector | Technology | Media |
52-Week High | $620.59 | $86.22 |
52-Week Low | $393.42 | $67.27 |
Enterprise Value | $16.52B | $31.66B |
Dividend Yield | — | 3.72% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Omnicom Group (OMC) trades at $85.45, up 0.95% with a bullish technical outlook and strong institutional support. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Recent acquisition of Interpublic Group has driven 6.1% organic revenue growth and margin expansion, though 2025 saw a net loss of $54.5 million. Analyst consensus price target stands at $107 with 32% buy ratings.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.97) and 4% dividend yield, supported by post-merger synergies and strong cash flow generation. Key risks include integration challenges from the Interpublic acquisition, competitive pressures in advertising services, and debt levels following the merger. The stock's current price offers 25% upside to consensus targets with institutional accumulation signaling confidence in the growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →